论文部分内容阅读
结直肠癌是最常见的癌症之一,每年可造成数十万人死亡,死亡率和发病率都呈逐年上升趋势。卡培他滨用于治疗结直肠癌已有十年的时间,其更好的疗效和用药依从性使其成为一种治疗结直肠癌的主要药物,但其同样有着不可忽视的毒副作用。研究发现卡培他滨疗效和毒副作用同其代谢基因的多态性有极大的关联,基因多态可在一定程度上解释其疗效和毒副作用的差异性。随着精准医疗的发展,制定精准高效的治疗策略,在基于分子生物学研究进展的基础上开展抗肿瘤药物的“个体化”治疗方案制订,是抗肿瘤药物治疗迫切需要研究的内容。卡培他滨药代动力学和药效学、药物相互作用、代谢相关基因多态性和临床应用的综述可以为卡培他滨个体化药物治疗方案的制订提供参考。
Colorectal cancer is one of the most common cancers, which can cause hundreds of thousands of deaths every year. The mortality rate and morbidity rate have been increasing year by year. Capecitabine has been used for 10 years in the treatment of colorectal cancer, and its better efficacy and compliance have made it a major drug for the treatment of colorectal cancer, but it also has undeniable side effects. The study found that capecitabine efficacy and side effects with its metabolic gene polymorphisms have a great relationship, gene polymorphisms can explain to some extent its efficacy and toxicity side effects. With the development of precision medicine and the development of precise and efficient treatment strategies, the development of “individualized” treatment plans for antitumor drugs based on the progress of molecular biology research is an urgent need for research on antitumor drug treatment. The review of capecitabine pharmacokinetics and pharmacodynamics, drug interactions, metabolic-related gene polymorphisms and clinical application may provide references for the formulation of individualized capecitabine medication regimens.